drugset / Trial / NCT02714530
Thoracal Radiotherapy and Tarceva
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if erlotinib given orally along with concurrent palliative irradiation to lung cancer improves local control compared to those treated with radiotherapy alone.
Timeline
- Start
- 2014-04-01
- Primary completion
- 2020-12-30
- Completion
- 2020-12-30
Outcome
Missed primary endpoint
Stopped (Enrollment): “Slow accrual”
paper median 14.5% reduction in the control arm A and 17.0% in the erlotinib arm B (p = 0.68). PMID 39148905 ↗
paper erlotinib and palliative thoracic RT for patients with advanced non-small cell lung cancer was well tolerated but did not improve the efficacy of the RT. PMID 39148905 ↗
Publications
- Nymoen HM, Alver TN, Horndalsveen H, Eide HA, Bjaanaes MM, Brustugun OT, Gronberg BH, Haakensen VD, Helland A. Thoracic radiation in combination with erlotinib-results from a phase 2 randomized trial. Front Oncol. 2024 Aug 1;14:1412716. doi: 10.3389/fonc.2024.1412716. eCollection 2024.
- Abravan A, Eide HA, Londalen AM, Helland A, Malinen E. Mapping Bone Marrow Response in the Vertebral Column by Positron Emission Tomography Following Radiotherapy and Erlotinib Therapy of Lung Cancer. Mol Imaging Biol. 2019 Apr;21(2):391-398. doi: 10.1007/s11307-018-1226-7.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 150 mg | Oral |